More game changing news.
Ensemble/Mosaic team brings in Canadian real estate firm in $1.5B Navy Yard play
https://www.bizjournals.com/philadelphia...c-brings-in-oxford-properties-group.html
"Oxford Properties Group, a global real estate firm based in Ontario, has entered into an agreement to own and develop three million square feet of life sciences space at the Philadelphia Navy Yard."
"The agreement involves Oxford investing in five properties owned by Ensemble as well as Ensemble/Mosaic’s future life sciences developments. The existing and future development is estimated to be valued at a combined $1.5 billion.
The existing buildings include: 300, 351 and 400 Rouse Blvd., and 4701 and 4751 League Island Blvd. Those buildings are fully leased to Iovance Biotherapeutics, Adaptimmune Therapeutics and WuXi Advanced Therapies."
"This is the first time Oxford has invested in Philadelphia and, with it, brings to 10 the number of life sciences markets it is involved across North America. The company already has a presence in Boston, Seattle and last week entered San Diego with a $464 million acquisition of a 13-building life sciences portfolio. In the last 12 months, it made $2 billion in life sciences related acquisitions across North America."
"The company has a strategy to build a life sciences portfolio and finds Philadelphia and the Navy Yard part of what is becoming a leading life sciences and innovation hub."
“We’re very bullish on the greater Philadelphia area as it relates to life sciences and as it relates to the future of the city,” said Chad Remis, executive vice president at Oxford, in an interview.
Oxford comes to Philadelphia based on similar reasons other developers and investors have put Philadelphia in their crosshairs including its educational and research institutions, National Institutes of Health and venture capital funding and talent. Added to that is the sheer demand for life sciences space, lack of supply, low vacancy rates and rising rents. “The Navy Yard and Philadelphia are the center for cell and gene therapy,” Remis said. “We believe in Cellicon Valley. We would like this to be our first but not our last investment in Philadelphia.”"